Megakaryocyte growth and development factor (MGDF), or thrombopoietin, has received considerable attention as a therapeutic agent for treating thrombocytopenia or for its use in the ex vivo culture of hematopoietic stem cells. MGDF is known to support the growth of a broad spectrum of hematopoietic precursors obtained from adult or neonatal tissues, but its effects on the growth of fetal progenitors and stem cells has not been studied. Human CD38 ϩ CD34 2ϩ progenitors and CD38 Ϫ CD34 2ϩ cells, a population that contains stem cells, were isolated from midgestation liver and grown under defined conditions with MGDF and various cytokines known to support the growth of primitive hematopoietic precursors. In clonal assays of colony-forming cells (CFCs), MGDF supported the growth of 15-25% of candidate stem cells when combined with granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), flk-2/flt3 ligand, or stem cell factor. MGDF was observed to strongly support the early stages of hematopoiesis and expansion of high proliferative potential CFCs. More mature progenitors were expanded nearly 78-fold in 1 wk of culture with MGDFϩSCFϩGM-CSF. MGDF alone was also found to support the short-term (2 d) survival of CD38
Ϫ CD34 2ϩ high proliferative potential CFCs. The effects of MGDF were more modest on CD38 ϩ CD34 2ϩ progenitors with only additive increases in colony formation being observed. These findings suggest that MGDF administration in fetuses and neonates may strongly affect the growth and mobilization of primitive hematopoietic progenitors and that MGDF may find use in the ex vivo growth and expansion of fetal stem cells. Abbreviations CFC, colony-forming cell FL, flk-2/flt3 ligand G-CSF, granulocyte colony-stimulating factor GM-CSF, granulocyte-macrophage colony-stimulating factor HPP, high proliferative potential LPP, low proliferative potential MGDF, megakaryocyte growth and development factor SCF, stem cell factor Megakaryocyte growth and development factor (MGDF) is the major regulator of megakaryocyte development and platelet production (reviewed in Refs. (1, 2) ). MGDF has been isolated from the sera of a number of mammalian species, in which its levels have been found to correlate inversely with peripheral blood platelet counts. Furthermore, the administration of MGDF has shown this cytokine to be a potent stimulator of thrombopoiesis, hence its other name thrombopoietin. The thrombopoietic effects of MGDF are the result of its ability to promote the growth and maturation of megakaryocytes. MGDF can stimulate, both in vitro and in vivo, an increase in megakaryocyte production and megakaryocyte ploidy. Administration of MGDF as a treatment for neonatal thrombocytopenia is being studied (3) (4) (5) .
MGDF also supports the growth of multipotent hematopoietic progenitors and stem cells. The administration of MGDF to mice after cytoablative injury has resulted in an accelerated recovery of myeloid and multilineage progenitors in addition to an increase in megakaryocytic progenitors (6) . Moreover, mice deficient in MGDF or its receptor, c-mpl, have reduced numbers of committed and multipotent progenitors (7, 8) , indicating a role for MGDF in the in vivo regulation of the early stages of hematopoiesis. These findings are further supported by observations of synergism between MGDF and other cytokines in increasing the growth of purified stem cells isolated from murine adult bone marrow (9, 10) . In humans, c-mpl mRNA expression was detected among adult bone marrow cells with the phenotypic characteristics (CD38 Ϫ   CD34   2ϩ ) associated with stem cells (11) . MGDF alone was shown to stimulate the production of megakaryocytes and neutrophils from CD38 Ϫ
CD34
2ϩ cells grown under serumdeprived conditions (12) . MGDF was also observed to synergize with a number of other early-acting growth factors to promote the growth of human primitive progenitors (13, 14) . MGDF has further found application in protocols used to expand hematopoietic progenitors ex vivo owing to the broad range of hematopoiesis supported by MGDF (2, 15) .
The primary site of MGDF production throughout human ontogeny is the liver (16 -18) . MGDF mRNA has also been detected in the fetal and adult bone marrow as well as in organs such as kidney and spleen. The levels of MGDF in plasma are higher in the fetus and neonate than in the adult (17, 19, 20) . The presence of MGDF in fetal hematopoietic tissues, such as the liver and bone marrow, indicates that this cytokine is a likely physiologic regulator of fetal hematopoiesis. Megakaryocyte progenitors isolated from human fetal tissues have been shown to respond to MGDF in vitro (21) (22) (23) (24) . MGDF has also been found to support the growth, when combined with either IL-3 or stem cell factor (SCF), of primitive progenitors isolated from murine fetal livers (25) . The response of fetal hematopoietic progenitors to cytokines has been found to differ from that of adult and even neonatal progenitors. Fetal progenitors generate a larger number of progeny and can differ in their response to cytokines compared with their adult counterparts (26 -31) . The role of MGDF in the regulation of the early stages of fetal hematopoiesis in the human is unclear. The goal of this study was to determine whether MGDF can support the growth of primitive hematopoietic progenitors isolated from human fetal liver because MGDF may have application in the realm of fetal and neonatal therapies. fetal liver cells used in this study has been published and is freely available on the internet (32) . Cytokines. Recombinant human MGDF, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF (GM-CSF), flk-2/flt3 ligand (FL), and SCF were provided by Amgen (Thousand Oaks, CA, U.S.A.). MGDF, G-CSF, and GM-CSF were used at 20 ng/mL unless otherwise stated. FL and SCF were used at 100 ng/mL and 50 ng/mL, respectively. These cytokine concentrations support the growth of a maximal number of colony-forming cells (CFCs) in assays performed under serum-deprived culture conditions. CFC assays. Myeloid CFC numbers were determined in triplicate double-layered clonal cultures as previously described (29, 30) . These cultures consisted of a total volume of 3 mL of serum-deprived culture medium (33) consisting of IMDM (Life Technologies, Grand Island, NY, U.S.A.) supplemented with 7.5 ϫ 10 Ϫ5 M ␣-thioglycerol (Sigma Chemical Co., St. Louis, MO, U.S.A.), 50 g/mL gentamicin, 2% fraction-V ethanol-extracted BSA (Roche Applied Science, Indianapolis, IN, U.S.A.), 200 g/mL human iron-saturated transferrin (Serologicals Proteins, Kankakee, IL, U.S.A.), 10 g/mL rh-insulin (Roche Applied Science), and 20 g protein/mL human LDL (Sigma Chemical Co.). SeaPlaque agarose (FMC, Rockland, ME, U.S.A.) was used as the semisolid matrix for these cultures at a concentration of 0.5% in the lower layer and 0.36% in the upper layer. After 3 wk of growth at 37°C in a fully humidified atmosphere, three classes of CFC were scored on the basis of the size of the hematopoietic colonies generated: high-proliferative potential (HPP) CFCs, lowproliferative potential (LPP) CFCs, and clusters. HPP-CFCs were defined by colonies that contained approximately 1 ϫ 10 4 to 1 ϫ 10 6 cells (29, 34) . LPP-CFCs were defined by colonies smaller than HPP-CFCs but Ͼ50 cells/colony. Clusters were defined as colonies that contained 10 -50 cells. The sum of all three CFC types is referred to as total CFCs. Multipotent CFCs that are capable of generating erythroid and myeloid cells were detected in methyl cellulose-based cultures as previously described in detail (35) .
METHODS

Isolation
Delayed-cytokine-addition experiments were used to study the effects of MGDF on the survival of CD38
Ϫ CD34 2ϩ Lin Ϫ fetal liver progenitors as previously reported (30, 31) . Briefly, clonal cultures were established using the serum-deprived culture medium with or without MGDF. A second addition of cytokines was performed at 1, 2, 3, 4, or 7 d after the initiation of culture, resulting in a final growth stimulus of MGDFϩSCFϩGM-CSF. Cytokines added after the initiation of the cultures were added in a volume of 30 L to the top of the semisolid cultures. Cultures stimulated with MGDFϩSCFϩGM-CSF from the beginning of culture were used to determine the number of CFCs seeded. SCF and GM-CSF were used in these cultures because these cytokines stimulate a broad range of myeloid progenitors and support the growth of a high frequency of HPP-CFCs (30) . Delta assay. The effects of MGDF, alone or in combination with other cytokines, on the growth of primitive progenitors during liquid culture were determined using the ⌬ assay (30) . Duplicate or quadruplicate liquid cultures were initiated with 900 CD38
2ϩ fetal liver cells in 1 mL of serum-deprived medium supplemented with or without cytokines. Primary CFCs were determined in parallel from triplicate cultures of 300 CD38 Ϫ CD34 2ϩ Lin Ϫ fetal liver cells grown in serumdeprived medium supplemented with SCFϩGM-CSF. After 7 d of liquid culture, cells were harvested and washed, and secondary clonal cultures were established using identical culture conditions as used for the primary assays. The secondary CFC assays were initiated with dilutions of the cultured cells. The dilutions were determined on the basis of the degree of cellular expansion observed with the different cytokine combinations and were made to seed~750 cells/culture when a sufficient degree of expansion had occurred. The change (⌬) in the number of cells and CFCs between the onset of liquid 1051 GROWTH OF FETAL PROGENITORS WITH MGDF culture and after 7 d of growth was determined by dividing the primary by the secondary values.
Data presentation and statistical analysis. The data are presented as the mean Ϯ 1 SEM of the results obtained from multiple experiments. The results of replicate CFC measurements for each individual experiment were averaged before use in calculating the mean of multiple experiments. The unpaired t test was used to determine the probability of differences between culture conditions from individual experiments. Differences were considered significant at p Յ 0.05.
RESULTS
MGDF supports colony formation by candidate stem cells.
For establishing that MGDF supports the growth of primitive progenitors from human fetal liver, purified progenitors were grown in clonal assays under serum-deprived conditions (Fig. 1) . Two precursor populations were studied, CD38
Lin Ϫ cells. The former population, lacking CD38 expression, contains stem cells, although it may also contain committed progenitors. The latter population, which expresses CD38, is composed of immature progenitors that do not have stem cell capacity (29, 32, 35) .
MGDF alone supported colony formation by a small number of CD38 Ϫ CD34 2ϩ Lin Ϫ candidate stem cells (Fig. 1 ). An average of 6 Ϯ 2 total CFCs/1.0 ϫ 10 3 CD38 Ϫ CD34 2ϩ Lin Ϫ cells were detected in cultures with MGDF, whereas no colony formation was detected in cultures in the absence of any added growth factors (p Յ 0.014, n ϭ 3). The effects of MGDF were compared with those of G-CSF, GM-CSF, FL, and SCF, growth factors that have been shown previously to support the growth of CD38 Ϫ CD34 2ϩ Lin Ϫ fetal liver cells (30, 31) . MGDF supported the growth of a greater number of total CFCs in two of three experiments compared with G-CSF and GM-CSF (p Ͻ 0.05). The numbers of CFCs supported by MGDF and FL were similar, whereas SCF supported the growth of more total CFCs than observed with MGDF, G-CSF, GM-CSF, and FL (p Ͻ 0.044, n ϭ 3). The level of proliferation supported by any of these cytokines individually was very low, with most colonies containing Ͻ50 cells.
Synergism in supporting colony formation was observed between MGDF and G-CSF, GM-CSF, FL, or SCF (Fig. 1 
Lin
Ϫ cells grown under any of the culture conditions shown in Fig. 1 , the possibility that MGDF affected the growth only of a more mature subpopulation of these cells existed. This possibility was disproved in experiments in which clonal cultures of CD38 Ϫ CD34 2ϩ Lin Ϫ cells were initiated with or without MGDF, followed by a second addition of growth factors that supported the growth of HPPCFCs. The combination SCFϩGM-CSF was used in these experiments to support the growth of HPP-CFCs (30) . As shown in Fig. 2A , the inclusion of MGDF in cultures stimulated by SCFϩGM-CSF did not significantly change the number of HPP-CFCs or LPP-CFCs detected (p Ͼ 0.22, n ϭ 3). Delaying the addition of growth factors by at least 2 d resulted in a significant decline in CFC viability in cultures initiated in the absence of cytokines (Fig. 2B) . In contrast, both HPP-CFCs and LPP-CFCs were better maintained by the presence of MGDF at the initiation of culture. CFCs did show a time-dependent decrease in cultures initiated with MGDF. The decreases were modest and usually insignificant during the first 3 d of culture. By the fourth day of culture, the numbers of CFCs detected in either cultures initiated with MGDF or those begun in the absence of cytokine had declined significantly. However, increased survival of CFCs cultured in the presence of MGDF was observed even when the addition of Lin Ϫ (p Յ 0.013, n ϭ 4 experiments; Fig. 1 ). In a dose-response experiment, the number of colonies supported by MGDF reached a peak at 20 ng/mL, but significant growth was observed even at 0.5 ng/mL (data not shown), indicating that the 20 ng/mL of MGDF used throughout this study was optimal. The numbers of total CFCs supported by MGDF was comparable to that supported by either G-CSF or FL but was somewhat less than that supported by GM-CSF (p Յ 0.016, n ϭ 3 of 4 experiments). SCF consistently supported more CFC growth than MGDF (p Ͻ 0.001, n ϭ 4 experiments).
Combining MGDF with any of the other cytokines tested resulted in increased growth of CD38 ϩ CD34 2ϩ Lin Ϫ progenitors, similar to what was observed with the cultures of candidate stem cells. However, the degree of synergism observed with the cytokine combinations was low, ranging from 1.1-to 1.5-fold, compared with the super-additive effects on the more primitive CD38 Ϫ CD34 
Ϫ cells were further assessed using the ⌬ assay (Fig. 3) . In seven experiments, the number of HPP-CFCs recovered from MGDF-stimulated cultures was 1.3 Ϯ 0.4-fold higher than input, which was comparable to the recovery of HPP-CFCs from SCF-stimulated cultures (p Ͼ 0.05). In the majority of experiments, the maintenance of HPP-CFCs by MGDF was significantly greater than that supported by G-CSF, GM-CSF, or FL (p Յ 0.05). The results were similar for LPPCFCs. The pattern observed using the ⌬ assay mirrored the pattern of colony growth from CD38
Lin Ϫ progenitors supported by individual growth factors (Fig. 1) . The ⌬ assay data further indicate that MGDF does promote the growth of a subset of early progenitors with a high level of proliferative potential even though HPP-CFCs were not detected in clonal cultures supported by MGDF alone.
Notable expansion of CFCs required combinations of cytokines (Fig. 3) . The synergism between MGDF and SCF resulted in the greatest average expansion of HPP-CFCs (⌬10.7 Ϯ 2.9) and LPP-CFCs (⌬26.8 Ϯ 6.9) observed with any of the cytokine pairs that contained MGDF (n ϭ7). However, the expansion of HPP-CFCs supported by MGDFϩSCF was less than half the 22.5 Ϯ 8.1-fold expansion stimulated by SCFϩGM-CSF, although the differences between these two groups were significant in only three of seven experiments. Thus, the combination MGDFϩSCF likely promotes the growth of the same population of HPP-CFCs as SCFϩGM-CSF, because combining MGDF with SCFϩGM-CSF promoted a similar expansion of HPP-CFCs as seen with SCFϩGM-CSF. The combination MGDFϩSCFϩGM-CSF did provide the greatest expansion of LPP-CFCs (⌬77.8 Ϯ 15.9), which was greater than the combined effects of MGDFϩSCF and SCFϩGM-CSF (p Ͻ 0.05 in at least six of seven experiments). These results indicate that the triadic cytokine combination supports the growth of a broader spectrum of progenitors that develop during the 1-wk culture period than do MGDFϩSCF or SCFϩGM-CSF.
DISCUSSION
Hematopoiesis is regulated by a variety of growth factors that act at different stages of hematopoiesis to support or inhibit the production of specific lineages of blood cells. The production of different cell lineages is in many cases regulated primarily by a single growth factor, such as the control of erythropoiesis by erythropoietin or support of megakaryocytopoiesis and thrombopoiesis by MGDF. In contrast, the early events in hematopoiesis are susceptible to regulation by a large number of cytokines, many of which are also important regulators of the final stages of hematopoietic development for specific cell lineages. MGDF is among these pleiotropic cytokines in that it has a broad spectrum of activity on hematopoiesis (1, 2) . Herein, we demonstrate that MGDF is an important regulator of the growth of early hematopoietic progenitors and, likely, stem cells in the human fetus.
Several lines of evidence indicate that MGDF is capable of supporting the growth and survival of fetal primitive progenitors and/or stem cells. MGDF was found to support the growth of CFCs found among CD38 Ϫ CD34 2ϩ Lin Ϫ cells. These candidate stem cells are known to require the presence of at least two cytokines for more than just a small number of CFCs to grow (30, 31) . Indeed, synergism was observed between MGDF and each of the other early-acting cytokines tested. Synergism in stimulating the growth of CD38 Ϫ CD34 2ϩ Lin Ϫ cells was also observed in the ⌬ assay, which demonstrated that MGDF could support the survival and expansion of CFCs. The size of colonies generated in the presence of MGDF and the degree of progenitor expansion supported by combinations of cytokines including MGDF was lower than with combinations such as SCFϩGM-CSF. This observation is attributed to the limited range of hematopoietic activity that MGDF has on the late stages of hematopoiesis and the relatively few numbers of megakaryocytes generated as a result of endomitosis. Although MGDF did not produce large colonies when paired with other early-acting cytokines, the results from delayedcytokine-addition experiments and from the ⌬ assay demonstrated that MGDF did support the growth of HPP-CFCs. Indeed, the ability of MGDF alone to support the short-term survival of HPP-CFCs observed in the delayed-cytokineaddition experiments was similar to that previously observed of SCF, FL, GM-CSF, G-CSF, and IL-3 on fetal CD38
Lin Ϫ cells (30, 31) . Because MGDF did not enhance the growth of CD38 Ϫ
CD34
2ϩ Lin Ϫ cells observed with SCFϩGM-CSF, it can be deduced that MGDF supports the growth of the same progenitors as affected by SCF and GM-CSF. Together these findings indicate that MGDF is active in supporting the growth of CD38
Lin Ϫ cells and can be included with SCF, FL, GM-CSF, G-CSF, and IL-3 in the category of fetal stem cell growth factors (30, 31) .
As with most tissues in the fetus, hematopoietic tissues undergo a level of growth unparalleled later in life to accommodate the need both to expand the size of the hematopoietic tissues and to keep pace with the increasing volume of peripheral blood. A number of studies have indicated differences in how fetal and postnatal progenitors respond to growth factors and growth inhibitors (27) (28) (29) (30) 36) . Fetal stem cells are also known to have a greater proliferative capacity both in vitro and in vivo (26, 37) . The findings in this study reveal further differences in how fetal and adult hematopoietic progenitors respond to cytokines. Although primitive progenitors/stem cells from both fetal and adult sources respond to MGDF, the response of fetal tissues seems to be greater. In a study by Kobayashi et 
Lin
Ϫ cells. Notably, the synergism between MGDF and SCF in supporting the growth of CFC among these candidate stem cells was as effective as SCFϩGM-CSF (30) . These findings contribute to previous observations that fetal progenitors/stem cells have a lower requirement for cytokines to support their growth (27) .
There is considerable interest in MGDF for its use in expanding transplantable hematopoietic cells ex vivo because of its early-acting properties as well as its potent thrombopoietic properties (2, 15) . Neonatal or fetal grafts are likely to benefit the most from ex vivo expansion because the numbers of progenitors available from these tissues are often too small for large adult recipients. The numbers of hematopoietic progenitors that can be obtained from midgestation fetal tissues exceeds that found in umbilical cord blood, and ex vivo expansion could further increase these numbers (33, 39) . Optimal conditions for the ex vivo expansion of progenitors need to be determined independently for fetal, neonatal, and adult tissues owing to the changes in the growth properties of hematopoietic precursors as they age. Nonetheless, optimal expansion depends on the presence of multiple growth factors that can support progenitors of different lineages as they develop from multipotent progenitors. Even though the number of fetal CD38 Ϫ CD34 2ϩ Lin Ϫ cells supported by SCFϩGM-CSF was the same as SCFϩGM-CSFϩMGDF, the latter combination supported a greater expansion of progenitors. This was likely due to MGDF's supporting the growth of CD38 ϩ CD34 2ϩ Lin Ϫ cells that developed during the course of the 7-d culture period. MGDF did support CFC growth from CD38 ϩ CD34 2ϩ Lin Ϫ cells, but there was no notable synergism between MGDF and the other cytokines examined. These data suggest that the progenitors found among the CD38 ϩ CD34 2ϩ Lin Ϫ cells that are responsive to MGDF differ from those affected by G-CSF, GM-CSF, FL, or SCF. This explanation accounts for the additive effects of these cytokines in supporting the growth of CD38 ϩ CD34 2ϩ Lin Ϫ cells and the greater expansion of progenitors observed with SCFϩGM-CSFϩMGDF.
The strong growth-promoting properties of MGDF on primitive hematopoietic progenitors from the fetus suggests that this cytokine may have use in fetal or neonatal therapy. MGDF may find use as a treatment for newborn thrombocytopenia and has been shown to be effective in increasing platelet counts in neonatal rhesus monkeys (3, 4) . Administration of MGDF has also been shown to increase the mobilization of progenitors and stem cells (40 -42) . Gene therapy performed on hematopoietic stem cells isolated from fetal and/or neonatal blood is being studied as a means to treat a number of inherited disorders of the hematopoi-1055 GROWTH OF FETAL PROGENITORS WITH MGDF etic system (43) (44) (45) (46) (47) . Mobilization of stem cells by MGDF administration may increase the yield of stem cells that can be harvested for therapy and returned to the fetal or neonatal circulation.
